Ardelyx (ARDX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.07
- Estimate
- -$0.05
- Surprise
- -41.2%
- Revenue (period 2026-06-30)
- $120.9M
- Score today
- 6.3/10
Revenue source: xbrl.
How the report landed
Ardelyx (ARDX) reported a wider loss than forecast — adjusted EPS of -$0.07 against the -$0.05 estimate (a 41.2% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates ARDX Sell at 6.3/10; no pre/post engine snapshot brackets this report.
0 of the last 4 quarters beat the estimate; this quarter's -41.2% surprise compares with a -11.6% four-quarter average. Next scheduled report: 2026-10-29.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Attractive valuation
What argues against it
- Concentration risk — Product: IBSRELA
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.0)
- Leverage penalty (D/E 1.9): -1.0
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.19
- Price target
- $3.56
- Stop
- $2.97
- Upside to target
- +11.4%
Risk check: RSI 29 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.
ARDX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $805.5M
- P/E (fwd)
- 10.7
- 52-week range
- $3.09–$8.40
- Off 52-week high
- 62.0%
- RSI (14)
- 29
- Volume vs avg
- 1.00×
- Score today
- 6.3/10